Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo

Biochemical and Biophysical Research Communications

Volumn 314, Issue 2, 2004, Pages 580-585

  Saha, Asish K ^a   Avilucea, Paco R ^a   Ye, Ji Ming ^b   Assifi, Murwarid M ^a   Kraegen, Edward W ^b   Ruderman, Neil B ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Acetyl CoA carboxylase; Dahl salt sensitive rat; Malonyl CoA

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INORGANIC SALT; MALONYL COENZYME A; PIOGLITAZONE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLAMP; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVATION; ENZYME ACTIVITY; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; IN VIVO STUDY; LIVER; MALE; MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RAT STRAIN; TIME;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0346374720     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.12.120     Document Type: Article

References (34)

1. Sreenan S.J., Sturis J., Pugh W., Burant C.F., Polonsky K.S. Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin and troglitazone. Am. J. Physiol. 271:1996;E742-E774.
2. Saltiel A.R., Olefsky J. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:1996;1661-1669.
3. Spiegelman B.M. PPARγ. Adipogenic regulator and thiazolidinedione receptor. Diabetes. 47:1998;507-514.
4. Burant C.F., Sreenan S., Hirano K., Tai T.A., Lohmiller J., Lukens J., Davidson N.O., Ross S., Graves R.A. Troglitazone action is independent of adipose tissue. J. Clin. Invest. 100:1997;2900-2908.
5. Unger R.H. Lipotoxic diseases. Annu. Rev. Med. 53:2002;319-336.
6. Unger R.H., Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J. 15:2001;312-321.
7. Mayerson A.B., Hundal R.S., Dufour S., Lebon V., Befroy D., Cline G.W., Enocksson S., Inzucchi S.E., Shulman G.I., Petersen K.F. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 51:2002;797-802.
8. Bajaj M., Suraamornkul S., Pratipanawatr T., Hardies L.J., Pratipanawatr W., Glass L., Cersosimo E., Miyazaki Y., DeFronzo R.A. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes. 52:2003;1364-1370.
9. Ye J.M., Frangioudakis G., Iglesias M.A., Furler S.M., Ellis B., Dzamko N., Cooney G.J., Kraegen E.W. Prior thiazolodinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver. Endocrinology. 143:2002;4527-4535.
10. Kurowski T.G., Saha A.K., Cunningham B.A., Holbert R.I., Colca J.R., Corkey B.E., Ruderman N.B. Malonyl coenzyme A and adiposity in the Dahl salt-sensitive rat: effects of pioglitazone. Metabolism. 45:1996;519-525.
11. Winder W.W., Hardie D.G. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am. J. Physiol. 277:1999;E1-E10.
12. Hardie D.G. The AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology. 144:2003;5179-5183.
13. Hardie D.G., Carling D. The AMP-activated protein kinase - fuel gauge of the mammalian cell? Eur. J. Biochem. 246:1997;259-273.
14. Ruderman N.B., Saha A.K., Vavvas D., Witters L.A. Malonyl-CoA, fuel sensing, and insulin resistance. Am. J. Physiol. 276:1999;E1-E18.
15. Salt I.P., Johnson G., Ashcroft S.J., Hardie D.G. AMP-activated protein kinase is activated by low glucose in all lines derived from pancreatic beta cells and may regulate insulin release. Biochem. J. 335:1998;533-539.
16. Itani S.I., Saha A.K., Kurowski T.G., Coffin H.R., Tornheim K., Ruderman N.B. Glucose autoregulates its uptake in skeletal muscle: involvement of AMP-activated protein kinase. Diabetes. 52:2003;1635-1640.
17. Fryer L.G., Parbu-Patel A., Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem. 277:2002;25226-25232.
18. Hawley S.A., Gadalla A.E., Olsen G.S., Hardie D.G. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes. 51:2002;2420-2425.
19. Combs T.P., Wagner J.A., Berger J., Doebber T., Wang W.J., Zhang B.B., Tanen M., Berg A.H., O'Rahilly S., Savage D.B., Chatterjee K., Weiss S., Larson P.J., Gottesdiener K.M., Gertz B.J., Charron M.J., Scherer P.E., Moller D.E. Induction of adipocyte complement-related protein of 30 kiloDaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology. 143:2002;998-1007.
20. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., Yamashita S., Noda M., Kita S., Ueki K., Eto K., Akanuma Y., Froguel P., Foufelle F., Ferre P., Carling D., Kimura S., Nagai R., Kahn B.B., Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8:2002;1288-1295.
21. Tomas E., Tsao T.S., Saha A.K., Murrey H.E., Zhang C.C., Itani S.I., Lodish H.F., Ruderman N.B. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc. Natl. Acad. Sci. USA. 99:2002;16309-16313.
22. Wu X., Motoshima H., Mahadev K., Stalker T.J., Scalia R., Goldstein B.J. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes. 52:2003;1355-1363.
23. Saha A.K., Vavvas D., Kurowski T.G., Apazidis A., Witters L.A., Shafrir E., Ruderman N.B. Malonyl-CoA regulation in skeletal muscle: its link to cell citrate and the glucose-fatty acid cycle. Am. J. Physiol. 272:1997;E641-E648.
24. Park H., Kaushik V.K., Constant S., Prentki M., Przybytkowski E., Ruderman N.B., Saha A.K. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J. Biol. Chem. 277:2002;32571-32577.
25. ′ for varying pH and pMg for the creatine kinase, adenylate kinase and ATP hydrolysis equilibria permitting quantitative bioenergetic assessment J. Exp. Biol. 198:1995;1775-1782.
26. Corkey B.E., Duszynski J., Rich T.L., Matschinsky B., Williamson J.R. Regulation of free and bound magnesium in rat hepatocytes and isolated mitochondria. J. Biol. Chem. 261:1986;2567-2574.
27. Unger R.H., Orci L. Lipoapoptosis: its mechanism and its diseases. Biochim. Biophys. Acta. 1585:2002;202-212.
28. Saha A.K., Kurowski T.G., Colca J.R., Ruderman N.B. Lipid abnormalities in tissues of the KKAy mouse: effects of pioglitazone on malonyl-CoA and diacylglycerol. Am. J. Physiol. 267:1994;E95-E101.
29. Ruderman N.B., Cacicedo J.M., Itani S., Yagihashi N., Saha A.K., Ye J.M., Chen K., Zou M., Carling D., Boden G., Cohen R.A., Keaney J., Kraegen E.W., Ido Y. Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes. Biochem. Soc. Trans. 31:2003;202-206.
30. Muoio D.M., Seefeld K., Witters L.A., Coleman R.A. AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem J. 338:1999;783-791.
31. M.A. Iglesias, J.M. Ye, G. Frangioudakis, A.K. Saha, E. Tomas, N.B. Ruderman, G.J. Cooney, E.W. Kraegen, AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats, Diabetes 51 (2002) 2886-2894. Erratum in: Diabetes 52 (2003) 223-224.
32. Fisher J.S., Gao J., Han D.H., Holloszy J.O., Nolte L.A. Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am. J. Physiol. Endocrinol. Metab. 282:2002;E18-E23.
33. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F., Goodyear L.J., Moller D.E. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108:2001;1167-1174.
34. B. Brunmair, K. Staniek, F. Gras, N. Scharf, A. lthaym, R. Clara, M. Roden, E. Gnaiger, H. Nohl, W. Waldhausl, C. Furnsinn, Thiazolidinediones, like metformin, inhibit respiratory complex I and cell respiration in vitro, Br. J. Pharmacol. (2003) (in press).